Open AccessComparison between antineoplastic treatments with selective inhibitors (BRAF/MEK) and the new potentials combinatorial therapies for metastatic melanoma
Author(s) -
Beatriz Toledo Dal'Ava,
Natali Figueiredo de Souza,
Thays dos Santos Chagas,
Gustavo José Vasco Pereira
Publication year - 2022
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v11i14.36275
Subject(s) - trametinib , dabrafenib , vemurafenib , medicine , melanoma , adverse effect , cancer research , mek inhibitor , oncology , cancer , pharmacology , mapk/erk pathway , metastatic melanoma , kinase , biology , microbiology and biotechnology